AC Immune
ACIU
32 hedge funds and large institutions have $153M invested in AC Immune in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1,700% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 1
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
113% more funds holding
Funds holding: 15 → 32 (+17)
50% more capital invested
Capital invested by funds: $102M → $153M (+$50.8M)
9.26% more ownership
Funds ownership: 19.15% → 28.41% (+9.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$20.3M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$16.8M |
| 3 |
O
OrbiMed
New York
|
+$14.5M |
| 4 |
Temasek Holdings
Singapore
|
+$12.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$11.9M |
| 2 |
PC
PointState Capital
New York
|
-$4.39M |
| 3 |
LBC
Lawrence B. Cohen
|
-$57.3K |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$3.37K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LBC
26
Lawrence B. Cohen
| $119K | -$57.3K | -5,700 | -28% |
|
|
GCP
27
GSA Capital Partners
London,
United Kingdom
| $110K | +$139K | +13,801 | New |
|
28
Marshall Wace
London,
United Kingdom
| $107K | +$135K | +13,391 | New |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $32K | +$40.4K | +4,018 | New |
|
30
UBS Group
Zurich,
Switzerland
| $21K | +$25.3K | +2,519 | New |
|
|
EDRH
31
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $10K | -$3.37K | -335 | -21% |
|
32
Barclays
London,
United Kingdom
| $6K | +$7.76K | +772 | New |
|
|
33
Fidelity International
Hamilton,
Bermuda
| – | -$11.9M | -1,283,910 | Closed |
|
ACIU Hedge Fund Activity: Q3 2018 in Review
32 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q3 2018, worth a combined $153M — up 50% from $102M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ACIU positions and 1 closed out — a net gain of 17 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $20.3M. The largest seller was Fidelity International, exiting entirely with an estimated $11.9M sold.
- 32 institutional investors held AC Immune (ACIU) as of Q3 2018, up from 15 in Q2 2018.
- Funds reported $153M of AC Immune stock for Q3 2018, up 50% quarter-over-quarter.
- 18 funds opened new AC Immune positions in Q3 2018 and 1 closed out, a net change of +17 holders.
- The largest AC Immune buyer in Q3 2018 was BVF Inc, an estimated $20.3M added.
- The largest AC Immune seller in Q3 2018 was Fidelity International, an estimated $11.9M sold.
Based on aggregated 13F filings for Q3 2018.